Invention Grant
- Patent Title: CD80 and CD86 binding protein compositions and uses thereof
-
Application No.: US16333888Application Date: 2017-09-19
-
Publication No.: US11261233B2Publication Date: 2022-03-01
- Inventor: Yang Liu , Pan Zheng , Martin Devenport , Wei Wu , Xuexiang Du , Mingyue Liu , Fei Tang
- Applicant: ONCOC4, INC. , CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
- Applicant Address: US MD Rockville; US DC Washington
- Assignee: ONCOC4, INC.,CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
- Current Assignee: ONCOC4, INC.,CHILDREN'S RESEARCH INSTITUTE, CHILDREN'S NATIONAL MEDICAL CENTER
- Current Assignee Address: US MD Rockville; US DC Washington
- Agency: Polsinelli PC
- Agent Ron Galant
- International Application: PCT/US2017/052264 WO 20170919
- International Announcement: WO2018/053506 WO 20180322
- Main IPC: C07K14/705
- IPC: C07K14/705 ; C07K16/46 ; A61K38/00 ; A61P37/06 ; A61P35/00 ; C07K16/28 ; A61K39/395 ; C07K14/00 ; A61K39/00
Abstract:
This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.
Public/Granted literature
- US20190263889A1 CD80 and CD86 Binding Protein Compositions and Uses Thereof Public/Granted day:2019-08-29
Information query
